3KY fundamentals
HANSOH PHARMAC. HD-,00001 revenue breakdown overview
HANSOH PHARMAC. HD-,00001 revenue for the last year amounted to 1.62 B EUR, the most of which — 790.72 M EUR — came from its highest performing source at the moment, Oncology, the year earlier bringing 768.05 M EUR. The greatest contribution to the revenue figure was made by China — last year it brought HANSOH PHARMAC. HD-,00001 1.30 B EUR, and the year before that — 1.30 B EUR.
By source
2016
2017
2018
2019
2020
2021
2022
2023
0.00
350.00 M
700.00 M
1.05 B
1.40 B
Oncology
Central Nervous System Diseases
Metabolic Diseases and Others
Anti-infective Diseases
Gastrointestinal
Diabetes
Other
Currency: EUR
2016
2017
2018
2019
2020
2021
2022
2023
Oncology
457.65 M
473.77 M
745.23 M
768.05 M
790.72 M
Central Nervous System Diseases
281.46 M
157.88 M
228.15 M
207.80 M
175.22 M
Metabolic Diseases and Others
149.48 M
185.13 M
173.08 M
155.36 M
166.50 M
Anti-infective Diseases
237.12 M
212.49 M
204.36 M
173.72 M
162.66 M
Gastrointestinal
—
—
—
—
—
Diabetes
—
—
—
—
—
Other
—
—
—
—
—
By country
2016
2017
2018
2019
2020
2021
2022
2023
0.00
350.00 M
700.00 M
1.05 B
1.40 B
China
Currency: EUR
2016
2017
2018
2019
2020
2021
2022
2023
China
1.13 B
1.03 B
1.35 B
1.30 B
1.30 B